Comerica Bank Sells 9,402 Shares of Eli Lilly and Company $LLY

Key Points

• Comerica Bank sold 9,402 shares of LLY (a 0.6% reduction) in Q4 but still owns 1,485,360 shares valued at about $1.596 billion, making Eli Lilly its largest holding (6.4% of the bank’s portfolio).
• Eli Lilly reported a Q1 beat — $19.8B revenue and $8.55 non‑GAAP EPS versus consensus — and raised 2026 guidance to $82–85B revenue and $35.50–37 EPS, triggering analyst upgrades and a stock rally.
• Key commercial and regulatory drivers include early traction for oral GLP‑1 Foundayo (>20,000 patients) and an FDA proposal to limit compounding of GLP‑1 ingredients, which could support pricing and share, although competitive and payer/pricing risks persist (e.g., Novo’s oral rollout).

Comerica Bank decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,485,360 shares of the company's stock after selling 9,402 shares during the period. Eli Lilly and Company comprises 6.4% of Comerica Bank's holdings, making the stock its largest holding. Comerica Bank owned approximately 0.16% of Eli Lilly and Company worth $1,596,286,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after acquiring an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. boosted its position in shares of Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock worth $1,587,000 after acquiring an additional 10 shares in the last quarter. Tanager Wealth Management LLP boosted its position in shares of Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after acquiring an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 1.5% during the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after acquiring an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC boosted its position in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after acquiring an additional 10 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Morgan Stanley reiterated an "overweight" rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a research report on Friday. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a "buy" rating in a research note on Friday. Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a research note on Thursday, February 19th. Finally, Truist Financial reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,218.93.

Eli Lilly and Company Price Performance

LLY stock opened at $965.19 on Friday. The company has a fifty day moving average price of $947.05 and a 200-day moving average price of $984.98. The company has a market capitalization of $911.93 billion, a P/E ratio of 42.06, a PEG ratio of 1.10 and a beta of 0.48. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 115.33%. The company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 33.79 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.